The global MicroRNA (miRNA) market size was USD 1230.3 Million in 2022 and is expected to register a revenue CAGR of 19.9% over the forecast period, according to the latest report by Reports and Data.

miRNAs serve as valuable biomarkers due to their ease of detection and resilience against degradation. MicroRNAs are petite non-coding RNA molecules that govern gene expression and play a crucial role in diverse biological processes. Consequently, they have been extensively investigated as prospective biomarkers for ailments such as cancer, cardiovascular disease, and neurological disorders. The identification of alterations in miRNA expression levels in bodily fluids like blood, urine, or saliva enables the diagnosis of diseases. Additionally, it facilitates the monitoring of disease progression and treatment effectiveness. For instance, variations in miRNA expression levels are employed to evaluate the efficacy of a therapy or guide the selection of an alternative treatment, if necessary. These factors collectively contribute significantly to the burgeoning revenue growth of the market.

The rising demand for Next Generation Sequencing (NGS) is fueled by its exceptional attributes, including unparalleled throughput, scalability, and expeditiousness. NGS stands as a high-throughput DNA sequencing technology that empowers researchers to rapidly and accurately sequence vast amounts of genetic material. By generating millions or even billions of DNA sequence reads in a single run, NGS enables researchers to swiftly amass extensive datasets, thus contributing to the remarkable revenue growth of the market. The unparalleled accuracy rates of NGS technologies instill confidence in the generated data, while the ability to concurrently sequence multiple samples diminishes the need for extensive experimentation, saving valuable time and resources. Furthermore, the advent of NGS technologies has resulted in a reduction in the cost of DNA sequencing, rendering it more economically viable for researchers to generate substantial volumes of sequencing data. NGS technologies find diverse applications, encompassing gene expression analysis, genetic variation analysis, as well as genome assembly and annotation, all of which propel the market's revenue growth.

The surging demand for microarray analysis tools stems from their vital role in scrutinizing the expression levels of microRNAs (miRNAs) across various samples and conditions, thereby driving significant revenue growth in the market. These tools enable researchers to concurrently assess the expression levels of hundreds or even thousands of miRNAs in a single experiment, presenting a high-throughput approach to studying miRNA expression. Moreover, microarray analysis tools facilitate the analysis of multiple samples, diminishing the need for excessive experimentation and conserving valuable time and resources. By boasting high accuracy rates, they excel at detecting subtle alterations in miRNA expression levels, rendering them a dependable means of gauging miRNA expression. Additionally, they enable the comparison of miRNA expression profiles across diverse samples or conditions, empowering researchers to identify differentially expressed miRNAs that may be involved in specific biological processes or diseases. All these factors collectively contribute to the remarkable revenue growth of the market.

A microRNA (miRNA) is a diminutive, single-stranded RNA molecule that exists in animals, plants, and various viruses. miRNAs play a pivotal role in post-transcriptional gene expression regulation and RNA silencing. They complement messenger RNA (mRNA) in suppressing gene expression and also oversee critical cellular functions, including cell differentiation, proliferation, and apoptosis. Their significance extends to cell physiology, development, and numerous pathological processes, such as viral infections, autoimmune diseases, and carcinogenesis. These abundant molecules can be found in various types of mammalian cells. Researchers employ microRNA sequencing, a form of RNA sequencing utilizing next-generation DNA sequencing technology, to investigate miRNA isoforms, tissue-specific expression patterns, and associations with diseases.

Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/1418

Some of the prominent players profiled in the global MicroRNA (miRNA) market include Merck KGaA, Horizon Discovery Ltd, Synlogic, QIAGEN, GeneCopoeia, Inc, New England Biolabs, Quantabio, NanoString, BioGenex, and SeqMatic LLC.

Some Key Highlights from the Report

• The segment encompassing kits, reagents, and consumables is poised to claim a substantial share of revenue during the forecast period. MicroRNAs (miRNAs), being small non-coding RNA molecules that play pivotal roles in the regulation of gene expression, necessitate a diverse array of kits, reagents, and consumables for comprehensive research. MiRNA expression profiling kits enable researchers to concurrently evaluate the expression levels of multiple miRNAs within a sample. To facilitate the study of miRNA, reverse transcription kits are employed to convert miRNA into complementary DNA (cDNA), which can then be amplified and analyzed through techniques like quantitative polymerase chain reaction (qPCR) or next-generation sequencing. MiRNA extraction kits are instrumental in isolating miRNA from biological samples, such as tissues, cells, and body fluids. Furthermore, miRNA quantitation kits empower researchers to determine the precise quantity of miRNA present in a given sample. These factors collectively propel revenue growth within this segment.
• The qRT-PCR sector is likely to account for a sizable revenue share during the projected period. The quantitative real-time polymerase chain reaction (qRT-PCR) is an amplifying and quantifying method for particular DNA or RNA sequences. It is a sensitive and specific method for identifying and quantifying gene expression in a material. Because qRT-PCR identifies extremely little quantities of nucleic acids, it is suitable for detecting low-abundance genes or analyzing samples with small amounts of starting material, which is boosting sector revenue growth. qRT-PCR accurately counts the quantity of target nucleic acid in a sample, allowing researchers to quantitatively compare gene expression across samples or circumstances.
• In 2021, the cancer segment held the largest share of revenue. MiRNAs play a significant role in cancer development by modulating the expression of oncogenes and tumor suppressor genes. Oncogenes promote cell proliferation and survival, and their excessive activity contributes to the onset of cancer. Conversely, tumor suppressor genes impede cell proliferation and foster cell death, and their inactivation contributes to cancer development. MiRNAs exert control over the expression of both oncogenes and tumor suppressor genes by binding to complementary sequences in their messenger RNA (mRNA) and impeding their translation into proteins. This crucial regulatory mechanism propels revenue growth within the segment.
• The segment comprising academic and research institutes is projected to experience a significantly rapid growth rate in revenue over the forecast period. Within these institutes, miRNAs are subject to thorough examination due to their involvement in diverse biological processes, encompassing development, immune function, and stress response. Moreover, miRNAs are being intensively explored as potential therapeutic targets for a range of diseases, such as cancer, cardiovascular disease, and neurological disorders. These extensive research efforts contribute to the driving force behind the revenue growth observed within this segment.
• In 2022, the North American market commanded the largest share of revenue. The surge in demand for microRNA in this region can be attributed to its versatile applications in various biological processes, including development, cellular differentiation, and immune responses. This multifaceted utility serves as a key driving force behind the revenue growth observed within the market. Moreover, the escalating demand for miRNA-based diagnostics and therapies contributes significantly to the revenue growth in this region. Additionally, the presence of prominent market players further bolsters the revenue growth in North America.
• Singular Genomics Systems, Inc., a company that empowers researchers and clinicians through the use of novel next-generation sequencing (NGS) and multiomics technologies, announced a partnership with Lexogen on January 10, 2022, to demonstrate the G4 sequencing platform's compatibility with Lexogen's RNA research products, specifically the QuantSeq, CORALL, and LUTHOR library preparation kits. Lexogen, a pioneer in RNA research, allowed low-cost, streamlined RNA library production kits with complete transcript representation.

For the purpose of this report, Reports and Data has segmented the global MicroRNA (miRNA) market on the basis of Products Outlook, Research & Tools Outlook, Application Form Outlook, End-use Outlook, and Regional Outlook:

Products Outlook (Revenue, USD Million; 2022 - 2032)

• Instruments
• Kits, Reagents & Consumables
• Insolation & Purification
• Quantification & Detection
• Functional Analysis
• Others

Research & Tools Analysis (Revenue, USD Million; 2022 - 2032)

• qRT-PCR
• Biomarkers
• Next Gen Sequencing (NGS)
• Microarray Analysis Tools
• Functional Analysis Tools
• Extraction Tools
• Others

Application Form Outlook (Revenue, USD Million; 2022 - 2032)

• Cancer
• Infectious Diseases
• Immunological Disorders
• Cardiovascular Diseases
• Neurological Disease

End-use Outlook (Revenue, USD Million; 2022 - 2032)

• Power Generation
• Transportation Fuel
• Fertilizer Production
• Others

Regional Outlook (Revenue, USD Million; 2022-2032)

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Sweden
• BENELUX
• Rest of Europe
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Rest of LATAM
• Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
• Israel

Request a customization on the report @ https://www.reportsanddata.com/request-customization-form/1418

Thank you for taking the time to read our article. The report can be tailored to the needs of the client. Please contact us for more details, and our team will tailor the report to your specific requirements.

Explore Trending Links:

Non-Muscle Invasive Bladder Cancer Market Growth - https://www.reportsanddata.com/report-detail/non-muscle-invasive-bladder-cancer-market

Artemisinin Market Analysis - https://www.reportsanddata.com/report-detail/artemisinin-market

Respiratory Distress Syndrome Market Forecast - https://www.reportsanddata.com/report-detail/respiratory-distress-syndrome-market
About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyse consumer behaviour shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Power and Energy, and Chemicals. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @ https://www.reportsanddata.com/report

Browse Latest Blogs: https://www.reportsanddata.com/blogs

Browse Latest Press Release: https://www.reportsanddata.com/press-release

Browse Upcoming Reports: https://www.reportsanddata.com/upcoming-reports

Browse Press Release: https://www.reportsanddata.com/press-release/global-microrna-mirna-market